Ginsenosides have notable bioactivity in treating cardiovascular diseases, but the mechanisms of their combined use with Peroxiredoxin 6 (PRDX6) in myocardial injury remain unclear. This study explores the synergistic effects of Ginsenoside Rb1 (Gs-Rb1) and PRDX6, aiming to provide a theoretical foundation for their therapeutic potential. We established a rat model of isoproterenol (ISO)-induced myocardial injury and observed that combination therapy was more effective than single-drug treatments, as shown by ECG monitoring and Masson staining. We performed RNA sequencing (RNA-Seq) on the combination therapy group and the ISO group. The results indicated that, compared to the ISO group, the combination therapy alleviated myocardial injury by reducing inflammation, oxidative stress, and apoptosis. Further analyses, including cell morphology, apoptosis rates, HE staining, ROS fluorescence intensity, and inflammation-related proteins, confirmed that the combination therapy successfully inhibited apoptosis, managed oxidative stress, and lessened inflammation. Combined treatment with Gs-Rb1 and PRDX6 significantly inhibited cardiac tissue fibrosis in rats, leading to a marked decrease in serum CK and LDH levels. RNA-seq analysis revealed upregulated genes related to lipid metabolism and small molecule biosynthesis, while downregulated genes were associated with oxidative stress, inflammation, and apoptosis. Validation experiments confirmed the combined treatment's significant inhibition of apoptosis, ROS activity, and inflammation. These results support the effectiveness of the two-drug combination in suppressing key biological processes in cardiac tissue, suggesting potential mechanisms for combating cardiac fibrosis. This study clarifies how Gs-Rb1 and PRDX6 work together to protect against myocardial damage, demonstrating that their combined therapy reduces inflammation, apoptosis, and oxidative stress. This highlights a new avenue for developing ginseng-based treatments.
Objective. To investigate the expression of glutathione peroxidase 2 (GPX2) in human lung adenocarcinoma tissues and its effect on the biological function of lung adenocarcinoma A549 cells. Methods. The expression of GPX2 in lung adenocarcinoma and its effect on survival were analyzed by the TCGA database and the GEPIA 2 database. A total of 45 cases of primary lung adenocarcinoma tissue specimens and 45 cases of their paracancerous tissue specimens were collected, and the expression of GPX2 in the two types of tissues was detected by immunohistochemistry. Lung adenocarcinoma A549 cells were divided into the GPX2 overexpression group (GPX2), the GPX2 knockdown group (si-GPX2), the empty vector group (Vector), the siRNA negative control group (si-NC), and the WT group; the mRNA level and protein expression of GPX2 in each group of A549 cells were detected by real-time fluorescence quantitative PCR and Western blotting; the proliferation activity of each group of cells was detected by the CCK-8 assay; the effect of GPX2 on cell migration and invasion ability was detected by the scratch assay and the Transwell invasion assay; the apoptosis of each group of cells was detected by flow cytometry; Western blotting was performed to detect the expression levels of Bax, Bcl-2, E-cadherin, vimentin, and MMP2 and MMP9 proteins in each group of cells. Results. Bioinformatics analysis showed that the expression of GPX2 was strongly correlated with the prognosis of lung adenocarcinoma patients ( ). The positive expression rates of GPX2 in lung adenocarcinoma and its paracancerous tissues were 66.0% and 15.7%, respectively ( ). The results of RT-qPCR and Western blotting showed that the expression level of GPX2 mRNA and protein in A549 cells in the GPX2 group increased, which was significantly higher than that in the WT group ( ); the expression levels of GPX2 mRNA and protein in A549 cells in the si-GPX2 group were the same, that is, significantly lower than the WT group ( ). GPX2 overexpression promoted the proliferation, migration, and invasion of A549 cells and inhibited their apoptosis; the results in the si-GPX2 group were opposite to those in the GPX2 group. Compared with the WT group, the expression of Bcl-2, vimentin, and MMP2 and MMP9 protein in the GPX2 group increased ( ), while the expression of Bax and E-cadherin protein decreased in the GPX2 group ( ); the results in the si-GPX2 group were opposite to those in the GPX2 group. Conclusion. The expression of GPX2 in lung adenocarcinoma is related to the prognosis of patients. It is proved that GPX2 can promote the migration and invasion of lung adenocarcinoma cells and is related to the EMT/β-catenin pathway. Thus, GPX2 is expected to be an important target for the diagnosis and treatment of lung adenocarcinoma.
Background: The rising incidence of breast cancer and its heterogeneity necessitate precise tools for predicting patient prognosis and tailoring personalized treatments. Epigenetic changes play a critical role in breast cancer progression and therapy responses, providing a foundation for prognostic model development.Methods: We developed the Machine Learning-derived Epigenetic Model (MLEM) to identify prognostic epigenetic gene patterns in breast cancer. Using multi-cohort transcriptomic datasets, MLEM was constructed with rigorous machine learning techniques and validated across independent datasets. The model’s performance was further corroborated through immunohistochemical validation on clinical samples.Results: MLEM effectively stratified breast cancer patients into high- and low-risk groups. Low-MLEM patients exhibited improved prognosis, characterized by enhanced immune cell infiltration and higher responsiveness to immunotherapy. High-MLEM patients showed poorer prognosis but were more responsive to chemotherapy, with vincristine identified as a promising therapeutic option. The model demonstrated robust performance across independent validation datasets.Conclusion: MLEM is a powerful prognostic tool for predicting breast cancer outcomes and tailoring personalized treatments. By integrating epigenetic insights with machine learning, this model has the potential to improve clinical decision-making and optimize therapeutic strategies for breast cancer patients.
Background: Breast cancer remains a leading cause of mortality among women worldwide, emphasizing the urgent need for innovative prognostic tools to improve treatment strategies. Anoikis, a form of programmed cell death critical in preventing metastasis, plays a pivotal role in breast cancer progression.Methods: This study introduces the Artificial Intelligence-Derived Anoikis Signature (AIDAS), a novel machine learning-based prognostic tool that identifies key anoikis-related gene patterns in breast cancer. AIDAS was developed using multi-cohort transcriptomic data and validated through immunohistochemistry assays on clinical samples to ensure robustness and broad applicability.Results: AIDAS outperformed existing prognostic models in accurately predicting breast cancer outcomes, providing a reliable tool for personalized treatment. Patients with low AIDAS levels were found to be more responsive to immunotherapies, including PD-1/PD-L1 inhibitors, while high-AIDAS patients demonstrated greater susceptibility to specific chemotherapeutic agents, such as methotrexate.Conclusions: These findings highlight the critical role of anoikis in breast cancer prognosis and underscore AIDAS’s potential to guide individualized treatment strategies. By integrating machine learning with biological insights, AIDAS offers a promising approach for advancing personalized oncology. Its detailed understanding of the anoikis landscape paves the way for the development of targeted therapies, promising significant improvements in patient outcomes.
Objective The present study was undertaken to investigate the genetic diversity of Rumex patientia L. in distinct habitat types. Methods Eighty samples from 4 natural populations in Jilin Province of China were analyzed by inter-simple sequence repeats (ISSR). Results ISSR techniques produced 135 bands and 71 polymorphic bands, of which the polymorphic bands (PPB) accounted for 52.6% among natural populations; the gene diversity (H) was 0.1751, and Shannon's diversity index (I) was 0.2634. In the population, the percentage of polymorphic loci (P) was 25.93% and 37.04%, the genetic diversity index (H) was 0.0714–0.1124 and Shannon’s diversity index (I) was 0.1121–0.1676. Population E had the highest genetic diversity, however, population S had the lowest. Based on the species genetic differentiation analysis, the total Nei diversity index (Ht) of Rumex patientia L. from Jilin City was 0.1110 and the within-population genetic diversity (Hs) was 0.1751. The coefficient of genetic differentiation between population areas (GST) was 0.3662. The Gene flow between populations was 0.8654. Conclusion The results showed that the inter-population variation accounted for 36.62% of the total variation, and the intra-population variation accounted for 63.38%. Cluster analysis based on Nei’s genetic distance showed that the greatest genetic distance between E and S (0.1218) and the closest genetic distance between W and N (0.0794).